Effects of donor plasma and recipient characteristics on convalescent plasma treatment outcome of COVID-19

供体血浆和受体特征对 COVID-19 恢复期血浆治疗结果的影响

• 批准号: 10225219
• 负责人: Maria Laura Gennaro
• 金额: $ 75.39万
• 依托单位: RBHS-NEW JERSEY MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10225219
• 关键词: 2019-nCoV; Affect; Antibodies; Antibody Response; Antibody titer measurement; Antibody-Dependent Enhancement; Antigen Targeting; Biological Assay; Biological Markers; Blood; Blood Cell Count; Blood Cells; Blood Donations; Blood Transfusion; COVID-19; COVID-19 pandemic; Cells; Cessation of life; Characteristics; Clinical; Clinical Practice Guideline; Clinical Trials; Coagulation Process; Communicable Diseases; Complete Blood Count; Consent; Convalescent Hospitals; Critical Care; Development; Disease; Emergency Situation; Emergency treatment; FDA approved; Future; Hematologist; Hospitals; Immune; Immune response; Immunologic Markers; Immunologist; Immunophenotyping; Inflammatory Response; Infrastructure; Infusion procedures; Knowledge; Life; Link; Lung; New Brunswick; Outcome; Oxygen; Patients; Pharmaceutical Preparations; Pharmacology; Phenotype; Physicians; Plasma; Plasmapheresis; Property; Proteins; Protocols documentation; Reagent; Research; Resources; Respiratory System; Sampling; Severities; Side; Symptoms; Teaching Hospitals; Techniques; Testing; Therapeutic; Transfusion; Treatment Efficacy; Treatment outcome; University Hospitals; Viral Load result; Wood material; antibody-dependent cell cytotoxicity; cytokine; design; effectiveness evaluation; inflammatory marker; knowledge of results; medical schools; multidisciplinary; neutralizing antibody; novel; prognostic; programs; success; transfusion medicine

In the absence of FDA-approved pharmacological therapies, convalescent plasma infusion has rapidly emerged as a notable emergency therapy for severe cases of COVID-19. However, due to the emergency conditions under which this treatment has been practiced, little effort has been placed in characterizing the properties of the donor plasma and the clinical status of the COVID- 19 patients that can most benefit from the infusion. We have assembled a multidisciplinary team that leverages linked blood donation and blood transfusion programs at Robert Wood Johnson University Hospital and state-of-the-art resources for the study of antibody responses and plasma markers of COVID-19 severity. This team proposes to conduct a study that relates donor plasma properties (antibody titers and functions, and antigen targets) and recipient's clinical status (including peripheral blood cell immunophenotypes and various plasma markers of COVID-19 severity) to the success of convalescent plasma infusion. The new knowledge resulting from our plan will guide the development of rational clinical practice guidelines and the design of convalescent plasma clinical trials.

在缺乏fda批准的药物治疗方法的情况下，恢复期血浆输注已迅速成为治疗COVID-19重症病例的重要紧急治疗方法。然而，由于这种治疗是在紧急情况下实施的，因此很少有工作来描述供体血浆的特性和COVID- 19患者的临床状态，而这些患者最能从输血中受益。我们组建了一个多学科团队，利用罗伯特·伍德·约翰逊大学医院的相关献血和输血项目，以及最先进的资源，研究COVID-19严重程度的抗体反应和血浆标志物。本团队拟开展供体血浆特性（抗体滴度和功能、抗原靶点）和受体临床状态（包括外周血免疫表型和各种COVID-19严重程度血浆标志物）与恢复期血浆输注成功的关系研究。从我们的计划中获得的新知识将指导合理临床实践指南的制定和恢复期血浆临床试验的设计。